Gene, cell and antibody-based therapies for the treatment of age-related macular degeneration
Gene, cell and antibody-based therapies for the treatment of age-related macular degeneration
Here we discuss antibody, cell and gene-based therapies that are currently available and under investigation for both wet and dry age-related macular degeneration (AMD). We initially discuss ocular anatomy, AMD modelling as well as the underlying pathophysiology of AMD. The antibody-based trials which have revolutionised the management of wet AMD are reviewed. The latest concepts in antibody therapy for wet AMD such as the port delivery systems, bispecific antibodies, designed ankyrin repeat protein (DARPINs) and brolucizumab are explored. Furthermore, the antibody-based trials targeting the complement pathway to reduce progression of geographic atrophy (GA) in dry AMD are discussed. Stem cell therapy and gene therapy are novel treatment modalities with no established clinical use in wet or dry AMD. Here, we discuss their efficacy so far in clinical trials. Their benefits and risk in the treatment of both wet and dry AMD are evaluated.
Choroidal neovascularisation, Gene therapy, Geographic atrophy, Macular degeneration, Monoclonal antibodies, Stem cell therapy
83-94
Lotery, Andrew
5ecc2d2d-d0b4-468f-ad2c-df7156f8e514
Akyo, Engin
4f5acd79-3867-460b-9c4b-f0f667812dfb
2020
Lotery, Andrew
5ecc2d2d-d0b4-468f-ad2c-df7156f8e514
Akyo, Engin
4f5acd79-3867-460b-9c4b-f0f667812dfb
Lotery, Andrew and Akyo, Engin
(2020)
Gene, cell and antibody-based therapies for the treatment of age-related macular degeneration.
Biologics: targets and therapy, 14, .
(doi:10.2147/BTT.S252581).
Abstract
Here we discuss antibody, cell and gene-based therapies that are currently available and under investigation for both wet and dry age-related macular degeneration (AMD). We initially discuss ocular anatomy, AMD modelling as well as the underlying pathophysiology of AMD. The antibody-based trials which have revolutionised the management of wet AMD are reviewed. The latest concepts in antibody therapy for wet AMD such as the port delivery systems, bispecific antibodies, designed ankyrin repeat protein (DARPINs) and brolucizumab are explored. Furthermore, the antibody-based trials targeting the complement pathway to reduce progression of geographic atrophy (GA) in dry AMD are discussed. Stem cell therapy and gene therapy are novel treatment modalities with no established clinical use in wet or dry AMD. Here, we discuss their efficacy so far in clinical trials. Their benefits and risk in the treatment of both wet and dry AMD are evaluated.
Text
Gene cell and antibody-based therapies for the treatment of age-related macular degeneration final
- Author's Original
Text
btt-252581-gene-cell-and-antibody-based-therapies-for-the-treatment-of
- Version of Record
More information
e-pub ahead of print date: 11 September 2020
Published date: 2020
Additional Information:
Publisher Copyright:
© 2020 Akyol and Lotery.
Keywords:
Choroidal neovascularisation, Gene therapy, Geographic atrophy, Macular degeneration, Monoclonal antibodies, Stem cell therapy
Identifiers
Local EPrints ID: 443996
URI: http://eprints.soton.ac.uk/id/eprint/443996
PURE UUID: 8261fcf4-0753-46ba-b837-1920b53c4459
Catalogue record
Date deposited: 21 Sep 2020 17:08
Last modified: 17 Mar 2024 02:57
Export record
Altmetrics
Contributors
Author:
Engin Akyo
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
